Skip to Content
Return to Navigation

Gilead’s Closed-Door Deal Sets Precedent For COVID-19 Drug Access-Devex, 6/16

Amid global conversations to ensure equitable access to future drugs and vaccines for COVID-19, Gilead Sciences, Inc. made its own side room deal. Over the past month, the U.S.-based company made an agreement with generic pharmaceutical companies in Egypt, India, and Pakistan to allow them to produce its drug remdesivir, an injectable antiviral medication, and currently the most promising drug for the treatment of the coronavirus. The deal allows these generic manufacturers to distribute the drug in 127 countries. Devex, 06/16/2020

Share this article: